ALK
Gli inibitori di ALK sono composti che mirano specificamente e inibiscono la chinasi del linfoma anaplastico (ALK), una tirosina chinasi recettoriale coinvolta nello sviluppo e nella progressione di alcuni tipi di cancro, inclusi il carcinoma polmonare non a piccole cellule e il neuroblastoma. Inibendo ALK, questi composti bloccano le vie di segnalazione che promuovono la crescita e la sopravvivenza delle cellule tumorali. Presso CymitQuimica, offriamo inibitori di ALK per supportare la tua ricerca in oncologia, terapie mirate contro il cancro e trasduzione del segnale.
Trovati 126 prodotti di "ALK"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
TP0427736 hydrochloride
CAS:TP0427736 hydrochloride is a novel and selective ALK5 inhibitor, capable of inhibiting Smad2/3 phosphorylation in A549 cells.Formula:C14H11ClN4S2Purezza:98.99%Colore e forma:SolidPeso molecolare:334.85MY10
CAS:MY10, a potent and orally active inhibitor of the receptor protein tyrosine phosphatase (RPTPβ/ζ), effectively reduces binge-like ethanol consumption andFormula:C15H10F6OS2Purezza:98.64%Colore e forma:SolidPeso molecolare:384.36Conteltinib
CAS:Conteltinib (CT-707) is an enzyme inhibitor with antitumor activity targeting FAK, ALK and Pyk2. It can be used to study lymphoma.Formula:C32H45N9O3SPurezza:98.12% - 99.54%Colore e forma:SolidPeso molecolare:635.82GW-6604
CAS:GW-6604 is an ALK5 inhibitor and shows clear antifibrotic effects resulting in liver function improvement.Formula:C19H14N4Purezza:99.6%Colore e forma:SolidPeso molecolare:298.34ALK/EGFR-IN-3
CAS:ALK/EGFR-IN-3 is a dual ALK and EGFR inhibitor that demonstrates potent anti-proliferative effects on various cancer cell lines, including H1975, PC9, and Baf3-Formula:C27H34ClN7O3SColore e forma:SolidPeso molecolare:572.12ALK/EGFR-IN-2
CAS:ALK/EGFR-IN-2 is a potent dual inhibitor targeting ALK and EGFR, promoting apoptosis and G0/G1 cell cycle arrest in cancer cells.Formula:C27H34ClN7O3SColore e forma:SolidPeso molecolare:572.12ALK/EGFR-IN-1
CAS:ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.Formula:C27H34ClN7O3SPurezza:98%Colore e forma:SolidPeso molecolare:572.12ALK-IN-6
CAS:ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).Formula:C26H29ClD3N5O3SPurezza:98%Colore e forma:SolidPeso molecolare:533.1UNC5293
CAS:UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.Formula:C30H42N6O2Colore e forma:SolidPeso molecolare:518.69ALK/ROS1-IN-1
CAS:ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).Formula:C30H35F3N6O3Purezza:98%Colore e forma:SolidPeso molecolare:584.63KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Formula:C26H30FN7OPurezza:98.49% - >99.99%Colore e forma:SolidPeso molecolare:475.56ALK-IN-27
CAS:Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.Formula:C23H22ClFN6OPurezza:99.71%Colore e forma:SolidPeso molecolare:452.91IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Formula:C25H20N6OPurezza:99.79%Colore e forma:SolidPeso molecolare:420.47CEP-14083
CAS:<p>CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.</p>Formula:C31H30N6O2Colore e forma:SolidPeso molecolare:518.61TGF-βRI inhibitor 3
CAS:<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Formula:C21H21NO4Colore e forma:SolidPeso molecolare:351.396WZH-15-125
CAS:WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.Formula:C33H45BrN8O5SColore e forma:SolidPeso molecolare:745.73ALK ligand-Linker Conjugate 1
CAS:ALK ligand-Linker Conjugate 1 is an ALK ligand-connector conjugate used for the synthesis of PROTACALK degrader-4.Formula:C36H45N5O3Colore e forma:SolidPeso molecolare:595.77DDO-02267
CAS:<p>DDO-02267 is a selective lysine-targeted covalent inhibitor of ALKBH5, with an IC50 value of 0.49 μM. It increases levels of N6-methyladenosine (m6A) and targets the ALKBH5-AXL signaling axis. DDO-02267 serves as a probe for studying the biological function of mRNA demethylases.</p>Formula:C18H12N2O7SColore e forma:SolidPeso molecolare:400.362PF-06463922 acetate
CAS:PF-06463922 acetate: ALK/ROS1 inhibitor, brain- penetrable, active vs crizotinib-resistant mutants, in NSCLC trials.Formula:C23H23FN6O4Colore e forma:SolidPeso molecolare:466.46ALK-IN-23
ALK-IN-23 inhibits ALK (IC50: 1.6-0.71 nM), hinders cancer cell spread, forms colonies in vitro, and reduces tumors in mice with low toxicity.Formula:C26H29ClN8O3SColore e forma:SolidPeso molecolare:569.08CDD-1115
CAS:<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Formula:C32H30N6O3Colore e forma:SolidPeso molecolare:546.619ALKBH5-IN-3
CAS:ALKBH5-IN-3 (Compound 20m) is a selective ALKBH5 inhibitor (IC50=21 nM), effectively stabilizes ALKBH5 in HepG2 cells and elevates m6A levels in intact cells.Formula:C11H7F3N2O3Purezza:98.32%Colore e forma:SolidPeso molecolare:272.18W23-1006
CAS:W23-1006 is a selective covalent ALKBH5 inhibitor. It binds to the ALKBH5 C200 residue with an IC50 value of 3.848 μM. The inhibitory activity of W23-1006 is approximately 30 times stronger than that of FTO and 8 times greater than that of ALKBH3. W23-1006 is applicable for research in triple-negative breast cancer (TNBC).Formula:C17H12BrN3O5Colore e forma:SolidPeso molecolare:418.198DA-0157
CAS:<p>DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.</p>Formula:C31H43BrN7O2PColore e forma:SolidPeso molecolare:656.597AZ12601011
CAS:AZ12601011 is a TGFBR1 kinase inhibitor that inhibits the growth of breast tumors.Formula:C19H15N5Purezza:98.81%Colore e forma:SolidPeso molecolare:313.36Zotizalkib
CAS:TPX-0131: potent, selective, CNS-ready, oral ALK inhibitor (WT IC50: 1.4nM, G1202R/L1196M IC50: 0.3nM) with robust antitumor effects.Formula:C21H20F3N5O3Purezza:98.7%Colore e forma:SolidPeso molecolare:447.41
